Fidelity Biosciences is set to join forces with a Devonshire Investors fund to become a new FMR-owned healthcare-focused investor called F-Prime Capital.
Fidelity Biosciences, an investment subsidiary of financial services conglomerate Fidelity Investments, agreed yesterday to merge with the technology fund run by private equity firm Devonshire Investors to form a new entity called F-Prime Capital.
Devonshire is a subsidiary of FMR, the parent company of Fidelity Investments. F-Prime will unite the two firms and continue their focus on companies operating in the life sciences, healthcare and technology sectors.
The various teams making up the new entity were previously spread across five…
